Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer

Table 2

Association of resistin expression with clinicopathological parameters in 392 Chinese Han patients with breast cancer.

Parameters	No. of patients	Positive resistin expression; (%)	value	Strongly positive resistin expression; (%)	value
Age (years)
≤35	19	16 (84.2%)	0.966	6 (31.6%)	0.466
35–55	238	197 (82.8%)		47 (19.7%)
>55	135	113 (83.7%)		29 (21.5%)
Tumor size (cm)
≤2	181	140 (77.3%)	0.012	33 (18.2%)	0.466
2–5	192	168 (87.5%)		45 (23.4%)
>5	19	18 (94.7%)		4 (21.1%)
Lymph node metastases
No	199	159 (79.9%)	0.080	45 (22.6%)	0.402
Yes	193	167 (86.5%)		37 (19.2%)
Tumor grade
I	19	11 (57.9%)	<0.001	0 (0.0%)	<0.001
II	265	215 (81.1%)		47 (17.7%)
III	108	100 (92.6%)		35 (32.4%)
Tumor stage
I	106	80 (75.5%)	0.042	20 (18.9%)	0.656
II	188	163 (86.7%)		43 (22.9%)
III	98	83 (84.7%)		19 (19.4%)
IV	0	0 (0.0%)		0 (0.0%)
Estrogen receptor
Negative	148	139 (93.9%)	<0.001	59 (39.9%)	<0.001
Positive	244	187 (76.6%)		23 (9.4%)
Progesterone receptor
Negative	192	177 (92.2%)	<0.001	63 (32.8%)	<0.001
Positive	200	149 (74.5%)		19 (9.5%)
HER2 expression
Negative (0–1^+)	184	147 (79.9%)	0.021	34 (18.5%)	0.001
Equivocal (2^+)	107	86 (80.4%)		14 (13.1%)
Positive (3^+)	101	93 (92.1%)		34 (33.7%)
Molecular classification
Luminal A	147	104 (70.7%)	<0.001	12 (8.2%)	<0.001
Luminal B	101	87 (86.1%)		11 (10.9%)
HER2-enriched	71	66 (93.0%)		33 (46.5%)
TNBC	73	69 (94.5%)		26 (35.6%)

Abbreviations: HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer.